Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents

FASEB Journal

Volumn 23, Issue 9, 2009, Pages 3171-3178

  Riccio, Gennaro ^a   Esposito, Giovanni ^a   Leoncini, Emanuela ^b   Contu, Riccardo ^c   Condorelli, Gianluigi ^c   Chiariello, Massimo ^a   Laccetti, Paolo ^a   Hrelia, Silvana ^b   D'Alessio, Giuseppe ^a   De Lorenzo, Claudia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

Heart failure; Her2; Herceptin; ImmunoRNase; Immunotherapy; Trastuzumab

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2 COMPACT ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; ERBICIN PANCREATIC RIBONUCLEASE FUSION PROTEIN; PROTEIN BCL XL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CARDIOTOXICITY; CELL SURVIVAL; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART WEIGHT; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; M MODE ECHOCARDIOGRAPHY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; STAINING; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARDIOTOXINS; DNA FRAGMENTATION; DRUG TOXICITY; ELECTROCARDIOGRAPHY; FIBROSIS; HUMANS; MICE; PROTEIN ENGINEERING; RECEPTOR, ERBB-2;

MUS;

EID: 70349317477     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-131383     Document Type: Article

References (28)

1. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182
2. Stebbing, J., Copson, E., and O'Reilly, S. (2000) Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat. Rev. 26, 287-290 (Pubitemid 30604039)
3. Baselga, J. (2000) Current and planned clinical trials with trastuzumab (Herceptin). Semin. Oncol. 27, 27-32 (Pubitemid 30778331)
4. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (Pubitemid 32222155)
5. Sparano, J. A. (2001) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin. Oncol. 28, 20-27
6. Chien, K. R. (2000) Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin. Oncol. 27, 9-14; discussion 92-100
7. Crone, S. A., Zhao, Y. Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., Ross, J., Jr., Chien, K. R., and Lee, K. F. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459-465 (Pubitemid 34546747)
8. Force, T., Krause, D. S., and Van Etten, R. A. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332-344 (Pubitemid 46652481)
9. Burris, H. A., 3rd, Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., Harris, J. L., Smith, D. A., Koch, K. M., Stead, A., Mangum, S., and Spector, N. L. (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23, 5305-5313
10. Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., and Jenkins, R. B. (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J. Clin. Oncol. 24, 3032-3038 (Pubitemid 46638937)
11. Schneider, J. W., Chang, A. Y., and Rocco, T. P. (2001) Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin. Oncol. 28, 18-26
12. De Lorenzo, C., Arciello, A., Cozzolino, R., Palmer, D. B., Laccetti, P., Piccoli, R., and D'Alessio, G. (2004) A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res. 64, 4870-4874 (Pubitemid 38924531)
13. De Lorenzo, C., Palmer, D. B., Piccoli, R., Ritter, M. A., and D'Alessio, G. (2002) A new human antitumor immunoreagent specific for ErbB2. Clin. Cancer Res. 8, 1710-1719 (Pubitemid 34633726)
14. De Lorenzo, C., Tedesco, A., Terrazzano, G., Cozzolino, R., Laccetti, P., Piccoli, R., and D'Alessio, G. (2004) A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br. J. Cancer 91, 1200-1204 (Pubitemid 39336263)
15. De Lorenzo, C., Cozzolino, R., Carpentieri, A., Pucci, P., Laccetti, P., and D'Alessio, G. (2005) Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 26, 1890-1895 (Pubitemid 41631261)
16. Troise, F., Cafaro, V., Giancola, C., D'Alessio, G., and De Lorenzo, C. (2008) Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. Br. J. Cancer 275, 4967-4979
17. De Lorenzo, C., Troise, F., Cafaro, V., and D'Alessio, G. (2007) Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. Br. J. Cancer 97, 1354-1360 (Pubitemid 350114782)
18. Bordoni, A., Biagi, P. L., Rossi, C. A., and Hrelia, S. (1991) Alpha-1-stimulated phosphoinositide breakdown in cultured cardiomyocytes: diacylglycerol production and composition in docosahexaenoic acid supplemented cells. Biochem. Biophys. Res. Commun. 174, 869-877
19. Angeloni, C., Leoncini, E., Malaguti, M., Angelini, S., Hrelia, P., and Hrelia, S. (2008) Role of quercetin in modulating rat cardiomyocyte gene expression profile. Am. J. Physiol. Heart Circ. Physiol. 294, H1233-H1243
20. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
21. Zhang, H., Wang, Q., Montone, K. T., Peavey, J. E., Drebin, J. A., Greene, M. I., and Murali, R. (1999) Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp. Mol. Pathol. 67, 15-25 (Pubitemid 29449450)
22. Vander Heiden, M. G., Chandel, N. S., Schumacker, P. T., and Thompson, C. B. (1999) Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ ADP exchange. Mol. Cell 3, 159-167
23. Lee, K. F., Simon, H., Chen, H., Bates, B., Hung, M. C., and Hauser, C. (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398
24. Erickson, S. L., O'Shea, K. S., Ghaboosi, N., Loverro, L., Frantz, G., Bauer, M., Lu, L. H., and Moore, M. W. (1997) ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 124, 4999-5011 (Pubitemid 28025125)
25. Baselga, J., Albanell, J., Molina, M. A., and Arribas, J. (2001) Mechanism of action of trastuzumab and scientific update. Semin. Oncol. 28, 4-11 (Pubitemid 33065104)
26. Kauraniemi, P., Hautaniemi, S., Autio, R., Astola, J., Monni, O., Elkahloun, A., and Kallioniemi, A. (2004) Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 23, 1010-1013 (Pubitemid 38250948)
27. Srinivas, U., Tagliabue, E., Campiglio, M., Menard, S., and Colnaghi, M. I. (1993) Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency. Cancer Immunol. Immunother. 36, 397-402 (Pubitemid 23146827)
28. Klapper, L. N., Vaisman, N., Hurwitz, E., Pinkas-Kramarski, R., Yarden, Y., and Sela, M. (1997) A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14, 2099-2109 (Pubitemid 27237013)